Germany's Fresenius SE Q2 core EPS rises 14%, lifts 2026 outlook

Fresenius SE & Co. KGaA

04/08/2026 21:23

Overview
Germany healthcare provider's Q2 revenue grew 6% organically, core EPS up 14% at constant currency
Q2 EBIT rose 10% at constant currency, driven by Kabi and Helios performance

Outlook
Company raised FY 2026 core EPS growth guidance to 10%-15% from 5%-10%
Company expects FY/26 organic group revenue growth of 4% to 7%
Fresenius SE says macroeconomic and geopolitical volatility increases operational uncertainty

Result Drivers
KABI GROWTH VECTORS - Fresenius Kabi's Biopharma, MedTech, and Nutrition segments drove strong revenue and EBIT growth, led by biosimilar launches and MedTech installations
HELIOS PROFITABILITY - Helios EBIT growth was supported by favorable pricing, higher patient admissions in Germany, and a surcharge on invoices for publicly insured patients
PRODUCTIVITY GAINS & LOWER INTEREST - Productivity improvements and lower interest expense contributed to higher group earnings

Company press release: ID:nEQx5dxba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EBIT
 
EUR 719 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Fresenius SE & Co KGaA is €54.00, about 21.7% above its August 4 closing price of €44.36
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Reuters Recommended Reads
Aug 4 - Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Aug 4 - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
Aug 4 - Pfizer Q2 results beat; raises 2026 revenue outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)